indications for Lasolvan (Ambroxol)
Expectorant, mucolytic agent
Actual information Lasolvan:
Lasolvan is a mucolytic preparation containing ambroxol hydrochloride as an active ingredient. Lasolvan is presented in various dosage forms (tablets, syrup, solution for inhalation and oral administration, capsules of prolonged action), which allows you to choose the optimal method of administration and dose for patients of different age groups and in various clinical situations.
Pharmacological properties Lasolvan:
Ambroxol, the active ingredient Lasolvan ®, increases the secretion of the glands of the respiratory tract. Ambroxol enhances the release of pulmonary surfactant and stimulates ciliary activity. This leads to improved mucus separation and excretion (mucociliary clearance). Activation of fluid secretion and increased mucociliary clearance facilitate the elimination of bronchial secretions and reduce cough. The local anesthetic effect of Ambroxol can be attributed to its sodium channel blocking properties. Studies in vitro have demonstrated that reversibly ambroxol and dose-dependently blocks the neuronal sodium channels. These pharmacological properties, leading to a rapid decrease in the severity of pain and pain-related discomfort in the nasal cavity and trachea, are consistent with additional observation of symptoms in clinical studies of the effectiveness of Ambroxol in the treatment of the upper respiratory tract. In vitro studies have shown that under the influence of the drug, the number of cytokines decreases, as well as the number of tissue-bound mononuclear cells and polymorphonuclear cells. Pharmacokinetics. Absorption of all oral forms of ambroxol is fast and fairly complete, with a linear relationship in the therapeutic range.
The maximum level in blood plasma is reached in 0.5–3 hours. In the therapeutic range, about 90% of the drug binds to blood plasma proteins. When administered orally, the distribution of ambroxol from the blood to the tissues is rapid, with a high concentration of the active substance in the lung tissue. Clinical studies have shown that CYP 3A4 is the predominant isoenzyme that metabolizes ambroxol. Ambroxol (Lasolvan) is metabolized mainly in the liver by conjugation. Plasma half-life is 10 hours. Total clearance is within 660 ml / min, renal clearance is about 8% of total clearance. There was no evidence that age and gender affect the pharmacokinetics of ambroxol within clinically significant limits, so there is no need for any dose adjustment.
Contraindications Lasolvan:
hypersensitivity to ambroxol or other components of the drug Lasolvan. In the case of rare congenital metabolic disorders, intolerance to the excipients of the drug is likely (see SPECIAL INSTRUCTIONS), in which case the drug is contraindicated.
Side effects Lasolvan:
as a rule, taking the drug Lasolvan ® is well tolerated. Digestive system disorders: mild manifestations of heartburn, dyspepsia, nausea, vomiting, diarrhea; disorders of the immune system, skin and subcutaneous tissues: skin rash, urticaria, angioedema, anaphylactic reactions (including anaphylactic shock) and allergic reactions. With the progression of lesions of the skin or mucous membranes, you should immediately consult a doctor and stop treatment with Ambroxol. Very rarely, severe skin lesions such as Stevens-Johnson and Lyell syndromes have been reported over time with mucolytic agents such as ambroxol. As a rule, they could be explained by the severity of the underlying disease or by taking concomitant medications.
Indications Lasolvan:
Lasolvan secretolytic therapy for acute and chronic diseases of the respiratory tract associated with impaired bronchial secretion and reduced mucus evacuation.
It is used for acute and chronic diseases of the respiratory tract with the release of viscous sputum.
Acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficulty in sputum discharge, bronchiectasis.
Lasolvan
Special instructions Lasolvan:
Use during pregnancy and lactation. Ambroxol crosses the placental barrier. Animal studies have not shown any direct or indirect adverse effects on pregnancy, embryo / fetal development, labor, or postnatal development. Extensive clinical experience after the 28th week of pregnancy has not shown evidence of a negative effect on the fetus. Despite this, you should adhere to the usual precautions when using medicines during pregnancy. Application Mucosolvan ® is not recommended especially in I trimester of pregnancy. Ambroxol passes into breast milk.
Therefore, Lasolvan® is not recommended to be taken during breastfeeding. However, do not expect a negative impact on an infant when receiving Lasolvan ® mother during lactation. Tablets Mucosolvan ® contain 684 mg of lactose in maximum recommended daily dose (120 mg). Patients with a rare form of hereditary galactose intolerance, Lapp lactose deficiency or malabsorption of glucose and galactose should not take this drug. Lasolvan® syrup does not contain sugar, so it can be prescribed to patients with diabetes mellitus; the syrup does not contain alcohol. The use of Lazolvan® in the form of a syrup is recommended for children under 12 years of age . The remains of gelatin capsules, sometimes detected in the feces, do not indicate the ineffectiveness of the drug, (the active substance is released from the capsules during its passage through the digestive tract).
Mode of application Lasolvan:
inside Ambroxol
1 capsule of prolonged action once a day. Capsules do not need to be opened or chewed. Swallow the capsule whole with water.
The capsules can be drunk with or without food.
